August 15, 2007 11:07 ET

ADM Tronics Reports First Quarter Fiscal Year 2008 Results

NORTHVALE, NJ--(Marketwire - August 15, 2007) - ADM Tronics Unlimited, Inc. (OTCBB: ADMT), a technology-based developer and manufacturer of unique, environmentally safe, health and life-enhancing technologies, today announced results for the first quarter ended June 30, 2007.

ADMT reported a net loss of $572,649 for the three months ended June 30, 2007, a decrease of $1,615,053 from the $2,187,702 loss for the three months ended June 30, 2006. This decrease was primarily the result of the exclusion of the majority of Ivivi Technologies Inc.'s (Ivivi) loss due to the deconsolidation of Ivivi following its October 2006 IPO that reduced our ownership to approximately 34%. Revenues for the quarter ended June 30, 2007, the second full quarter in which Ivivi Technologies, Inc.'s ("Ivivi") operating results were not fully consolidated with ADMT, were $293,086 as compared to $464,979 for the same period last year, which included Ivivi's operating results. See the accompanying Supplemental Pro Forma Financial Information that shows our results for the three months ended June 30, 2006 with Ivivi's results on one line to make it more comparative to our current period results. Our revenue for the current period was $293,086, which included $61,599 in sales of medical devices to Ivivi, compared to our pro forma revenue for the prior period of $247,560 for an increase of $45,526, or 18%.

Andre' DiMino, ADMT President, stated, "We are pleased with our continued growth for both our year-over-year and sequential periods. The exclusion of Ivivi's revenue during last year's quarter provides historical numbers with comparable results and transparency with respect to ADMT. We expect to see continued growth and acceptance of our water-based chemical products as well as building on our recent announcements, including the distribution agreement with Flora for the Demeter Certified Biodynamic Product Lines and the launch of our new division -- Aqua-Based Technologies."

"Our fiscal 2008 operating plan includes initiatives to expand market presence and penetration. To date, we have hired sales and marketing personnel; expanded our internet presence; and enhanced customer service. Those initiatives are just now beginning to show results and we expect to see the financial contribution from those efforts continue in future quarters. Additionally, our sales expectations through the exclusive manufacturing agreement with Ivivi is expected to increase revenue over the next 18 months," concluded DiMino.

About ADMT

ADMT is a technology based developer and manufacturer of unique, environmentally safe, health and life enhancing technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. Its diversified product technology areas are environmentally friendly, water based industrial chemicals; therapeutic, non invasive electronic medical devices; and, innovative personal care and topical dermatological products.

Forward-Looking Statements

This press release contains statements, which may constitute "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including those related to the Flora distribution agreement. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, those risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2007. The Company assumes no obligation to update the information contained in this press release.

                             ADM TRONICS UNLIMITED, INC.
                               Supplemental Pro-Forma
                                Financial Information

The following table compares the results of operations for the three months ended June 30, 2007 with the pro-forma results of operations for the three months ended June 30, 2006 as if Ivivi's operations were reported on one line, which ADMT believes provides a more informative comparison of the reporting periods.

The pro forma financial information set forth below should be read in conjunction with a reading of ADMT's historical financial statements. The pro forma information is presented for illustrative purposes only and is not intended to be indicative of ADMT's results of operations that may be reported in the future.

                                                          June 30, 2006
                                                            Pro Forma
                                                        Ivivi Operations
                                       June 30, 2007  Reported on One Line
                                   ------------------  ------------------

Revenues                           $          293,086  $          247,560
                                   ------------------  ------------------

Costs and expenses:
  Cost of sales                               170,059              85,594
  Research and development                      2,493                 262
  Selling, general and
   administrative                             248,719             145,724
                                   ------------------  ------------------

Total operating expenses                      421,271             231,580
                                   ------------------  ------------------

Operating (loss) income                      (128,185)             15,980

Interest and financing
 costs, net                                    25,143               2,253
Equity in net loss of Ivivi                  (469,607)                  -
Loss from Ivivi operations                          -          (2,205,935)
                                   ------------------  ------------------

Net loss                           $         (572,649) $       (2,187,702)
                                   ==================  ==================

Net loss per share, basic
 and diluted:                      $            (0.01) $            (0.04)
                                   ==================  ==================

Weighted average shares
 outstanding                               53,882,037          53,882,037

                             ADM TRONICS UNLIMITED, INC.
                              STATEMENTS OF OPERATIONS
                   FOR THE THREE MONTHS ENDED JUNE 30, 2007 AND 2006

                                         2007                  2006
                                  ------------------    ------------------

Revenues                          $          293,086    $          464,979
                                  ------------------    ------------------

Costs and expenses:
  Cost of sales                              170,059               122,955
  Research and development                     2,493               131,078
  Selling, general and
   administrative                            248,719             1,194,494
                                  ------------------    ------------------

Total operating expenses                     421,271             1,448,527
                                  ------------------    ------------------

Operating loss                              (128,185)             (983,548)

Interest and financing costs, net             25,143              (980,151)
Change in fair value of warrant
 and registration rights
 liabilities                                       -              (224,003)
Equity in net loss of Ivivi                 (469,607)                    -
                                  ------------------    ------------------

Net loss                          $         (572,649)   $       (2,187,702)
                                  ==================    ==================

Net loss per share, basic
 and diluted:                     $            (0.01)   $            (0.04)
                                  ==================    ==================

Weighted average shares
 outstanding                              53,882,037            53,882,037

                              BALANCE SHEET
                              JUNE 30, 2007


Current assets:
  Cash and cash equivalents                             $        2,335,871
  Accounts receivable, net of allowance for
    doubtful accounts of $900                                       46,637
  Receivables - Ivivi                                               35,285
  Inventories                                                      257,664
  Prepaid expenses and other current assets                         13,950

Total current assets                                             2,689,407

Property and equipment, net of accumulated
  depreciation of $6,722                                            47,922

Inventory - long term portion                                      153,614
Investment in Ivivi                                              2,281,124
Loan receivable and accrued interest, officer                       93,302
Other assets                                                        87,805

Total assets                                            $        5,353,174


Current liabilities:
  Accounts payable                                      $          162,615
  Accrued expenses and other current liabilities                    61,257

Total current liabilities                                          223,872

Stockholders' equity:
  Preferred stock, $.01 par value; 5,000,000 shares
    authorized, no shares issued and outstanding                         -
  Common stock, $.0005 par value; 150,000,000 shares
    authorized, 53,882,037 shares issued and outstanding            26,941
  Additional paid-in capital                                    30,410,124
  Accumulated deficit                                          (25,307,763)

Total stockholders' equity                                       5,129,302

Total liabilities and stockholders' equity              $        5,353,174

Contact Information